根据协议条款,阿斯利康将获得一种新型EGFR L858R变构抑制剂的独家选择权,获得其在全球开发和商业化的权利。Allorion有资格获得高达4000万美元的前期和近期付款,以及超过5亿美元的额外开发和商业里程碑付款。
[1] Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca. Retrieved January 2, 2024 from https://www.prnewswire.com/news-releases/allorion-therapeutics-announces-exclusive-option-and-global-license-agreement-for-novel-preclinical-stage-egfr-l858r-allosteric-inhibitor-program-with-astrazeneca-302023562.html
[2] AstraZeneca picks up a friend for Tagrisso in $40M upfront deal. Retrieved January 2, 2024 from https://www.fiercebiotech.com/biotech/astrazeneca-picks-friend-tagrisso-40m-upfront-deal